Supreme Court Ruling Will Have Little Effect on Future Direction of Reform, Says Healthcare Visionary
G. Steven Burrill Argues in His New Book That Patients, Providers, Payers, and Technology Are Driving Dramatic Changes to Healthcare With or Without the Legislation
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 03/26/12 -- As the U.S. Supreme Court hears oral arguments on the constitutionality of the Obama administration's healthcare reform law, a healthcare visionary says the outcome of the case will have little effect on the future direction of healthcare.
"Healthcare is reforming with or without the legislation," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm focused on the life sciences. "The most dramatic changes to healthcare are underway, and they are being driven not by legislation, but by patients, providers, payers, and technology."
Burrill addresses these issues in his new book Biotech 2012: Innovating in the New Austerity, Burrill & Company's 26th annual report on the life sciences industry. In it, Burrill examines the financial pressures being felt by both healthcare systems and innovators as aging populations, expanding demand for healthcare in emerging economies, and an epidemic of chronic disease strain global payers and providers struggling to contain costs.
Flagging R&D productivity, rising regulatory hurdles, and pricing pressures from governments are making it harder for companies to fund the development of innovative therapies needed to address the costliest and deadliest diseases today. In his book, Burrill reveals how these factors are driving investors, entrepreneurs, and innovators to develop new financing, business, and partnering models.
Through much of human history little has changed in man's approach to healthcare, Burrill says. The approach has been largely reactive, addressing symptoms as they arise with mixed and sometimes ineffective results. Doctors, positioned as unquestioned authorities, have often treated patients through trial and error.
Now, driven by a better understanding of the molecular basis of disease, information technology, and ubiquitous wireless connectivity, new approaches are emerging that are reshaping the way care is accessed and delivered. These changes are shifting power from the doctor to the patient and driving healthcare toward a focus on the prediction and prevention of disease.
"We are now at a point where the emergence of low-cost sequencing, targeted therapies, molecular diagnostics, and other technologies are finally moving us into the real world of personalized medicine," says Burrill. "That's coming as the convergence of information technology, wireless connectivity, and low-cost monitors will provide us with real-time information about our own health and wellness, and put individuals in unprecedented control of their own health."
Innovating in the New Austerity examines key developments in finance, regulation, policy, and other areas and looks at the challenges the industry faces and how it is responding. It's a critical resource for life sciences professionals who want to understand where the industry is going. The electronic edition is available today.
To purchase a copy or download the table of contents, a list of charts, and a sample chapter, go to . A single-user PDF can be purchased for $319. Discounts on multiuser licenses are available. The print edition, which will sell for $349, will be released in mid-April. The 352-page book features more than 200 charts and graphs. Pre-orders for the print edition are now being accepted.
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit:
Contact:
Daniel Levine
Managing Director
Burrill & Company
415-591-5449
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.03.2012 - 12:45 Uhr
Sprache: Deutsch
News-ID 128290
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 160 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Supreme Court Ruling Will Have Little Effect on Future Direction of Reform, Says Healthcare Visionary"
steht unter der journalistisch-redaktionellen Verantwortung von
Burrill & Company (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
